Revenue Streams: In Q4 2024, KalVista reported revenues of $1.206 million, aligning with a sustained focus on its pivotal drug development projects. However, this revenue stream is minimal compared to the operational expenditures.
Operational Efficiency: The gross profit was reported at $987,000, translating to a gross profit margin of 81.8% which highlights high efficiency in product development processes yet reflects low sales volumes.
Expense Analysis: Operating expenses soared to $48.46 million, leading to an operational loss of $48.46 million. R&D expenses loomed large at $25.25 million, indicating KalVista's ongoing commitment to drug advancements.
Liquidity Ratios: The current ratio stands at an impressive 9.90, indicating a very strong liquidity position, enabling the company to cover its short-term liabilities with ease. However, a concerning cash flow situation was reported with net cash used in operating activities amounting to -$15.1 million and a total cash at the end of the period of $31.79 million, suggesting potential forecasted liquidity concerns should cash burn rates persist.